APA (7th ed.) Citation

Martín, M., Martínez, N., Ramos, M., Calvo, L., Lluch, A., Zamora, P., . . . González‐Neira, A. (2015). Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009‐05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis. The oncologist (Dayton, Ohio), 20(2), 111-112. https://doi.org/10.1634/theoncologist.2014-0379

Chicago Style (17th ed.) Citation

Martín, Miguel, et al. "Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009‐05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis." The Oncologist (Dayton, Ohio) 20, no. 2 (2015): 111-112. https://doi.org/10.1634/theoncologist.2014-0379.

MLA (9th ed.) Citation

Martín, Miguel, et al. "Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009‐05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis." The Oncologist (Dayton, Ohio), vol. 20, no. 2, 2015, pp. 111-112, https://doi.org/10.1634/theoncologist.2014-0379.